Bupropion
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Prescription norepinephrine-dopamine reuptake inhibitor (NDRI) approved for major depressive disorder, seasonal affective disorder, and smoking cessation (marketed as Zyban). Unique among antidepressants for its lack of significant sexual side effects and weight-neutral to weight-loss profile. Also used off-label for ADHD. Carries a dose-dependent seizure risk. Dosage must be determined by your prescribing physician.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Prescription norepinephrine-dopamine reuptake inhibitor (NDRI) approved for major depressive disorder, seasonal affective disorder, and smoking cessation (marketed as Zyban). NutriStack rates the supporting evidence as strong. Common adult dosing is 150–450 mg daily (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: depression symptom relief, no sexual side effects, smoking cessation aid. 10 sources indexed (2018–2024), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Inhibits the reuptake of norepinephrine (NE) and dopamine (DA) by blocking the norepinephrine transporter (NET) and dopamine transporter (DAT). Does not significantly affect serotonin reuptake, which accounts for its distinct side effect profile. Also acts as a nicotinic acetylcholine receptor antagonist, contributing to its efficacy for smoking cessation.10
Dosing & protocol.
Can be taken with or without food. Do not crush, chew, or divide sustained/extended-release tablets. Space doses at least 8 hours apart for SR formulation.
Full safety detail.
Side effects
- Insomnia
- Dry mouth
- Agitation or anxiety
- Headache
- Nausea
- Tachycardia
- Seizure risk (dose-dependent)
- Tremor
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
7- 1Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trialsPMIDJi M, Feng J, Liu G · PloS one · 2024
Ji M, Feng J, Liu G. Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. PloS one. 2024
- 2Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trialsPMIDBakouni H, Sharafi H, Bahremand A et al. · Drug and alcohol dependence · 2023
Bakouni H, Sharafi H, Bahremand A et al.. Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials. Drug and alcohol dependence. 2023
- 3Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical TrialsPMIDAkbar D, Rhee TG, Ceban F et al. · CNS drugs · 2023
Akbar D, Rhee TG, Ceban F et al.. Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials. CNS drugs. 2023
- 4Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analysesPMIDSposito AC, Bonilha I, Luchiari B et al. · Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021
Sposito AC, Bonilha I, Luchiari B et al.. Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2021
- 5Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.PMIDElliott J, Johnston A, Husereau D et al. · PLoS One · 2020
Network meta-analysis of adult ADHD treatments found bupropion significantly reduced ADHD symptoms compared to placebo, with efficacy comparable to atomoxetine and guanfacine but lower than stimulants.
- 6Systematic Review and Meta-Analysis to Assess the Safety of Bupropion and Varenicline in PregnancyPMIDTurner E, Jones M, Vaz LR et al. · Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
Turner E, Jones M, Vaz LR et al.. Systematic Review and Meta-Analysis to Assess the Safety of Bupropion and Varenicline in Pregnancy. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. 2019
- 7Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.PMIDCortese S, Adamo N, Del Giovane C et al. · Lancet Psychiatry · 2018
Network meta-analysis of 133 RCTs found bupropion effective for ADHD symptoms across all age groups, though less efficacious than stimulants (methylphenidate, amphetamines); bupropion was among the best-tolerated non-stimulant options.
Reference material
3- 8Cipriani A et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018.Source linkedPMID
- 9Jorenby DE et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999.Source linkedPMID
- 10Clayton AH et al. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 2001.Source linkedPMID
Common questions.
Quick answers about Bupropion, drawn from the data on this page.
What is Bupropion?
Prescription norepinephrine-dopamine reuptake inhibitor (NDRI) approved for major depressive disorder, seasonal affective disorder, and smoking cessation (marketed as Zyban). Unique among antidepressants for its lack of significant sexual side effects and weight-neutral to weight-loss profile. Also used off-label for ADHD. Carries a dose-dependent seizure risk. Dosage must be determined by your prescribing physician.
What is Bupropion used for?
Commonly cited benefits of Bupropion include: Depression symptom relief; No sexual side effects; Smoking cessation aid; Weight-neutral to weight-loss effect; Improved motivation and energy. NutriStack rates the overall evidence as strong.
What is a typical dose of Bupropion?
A typical adult dose of Bupropion is 150–450 mg daily (as prescribed by your physician). The commonly recommended form is Sustained-release or extended-release tablet. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Bupropion?
Reported side effects include insomnia, dry mouth, agitation or anxiety, headache, nausea, tachycardia. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Bupropion?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Bupropion in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.